Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGT-002 in NASH
NCT06491576Phase 2Completed
- Sponsor
- Burgeon Therapeutics
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BGT-002 in Nonalcoholic steatohepatitis (NASH), sponsored by Burgeon Therapeutics. Started Mar 2023; status: completed.
02
Drugs
BGT-002
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06491576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491576.